Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX301 Alone or with Temozolomide in High-Grade Glioma
NCT06703255Phase 2Recruiting
- Sponsor
- Hanx Biopharmaceuticals
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of narazaciclib in glioma, glioblastoma (GBM), sponsored by Hanx Biopharmaceuticals. Started Jan 2025; status: recruiting.
02
Drugs
narazaciclib
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT06703255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703255.